

Table 1.22
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2013^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			38-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 38 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 38 Years ^d
All Sites	Both Sexes	4,683,633	4,777,436	5,281,162	13,793,147	14,017,809
	Male	2,371,817	2,408,477	2,654,461	6,558,326	6,635,084
	Female	2,311,816	2,368,959	2,626,701	7,234,821	7,382,725
Oral Cavity & Pharynx	Both Sexes	111,858	129,718	134,909	292,631	324,216
	Male	78,943	90,724	93,801	195,801	215,214
	Female	32,915	38,994	41,108	96,830	109,002
Esophagus	Both Sexes	21,605	26,812	26,884	36,756	43,489
	Male	17,134	21,074	21,110	28,826	33,848
	Female	4,471	5,738	5,774	7,930	9,641
Stomach	Both Sexes	38,885	46,951	47,520	78,761	91,003
	Male	22,739	27,768	28,102	44,833	52,171
	Female	16,146	19,183	19,418	33,928	38,832
Colon & Rectum	Both Sexes	393,064	452,807	462,351	1,160,780	1,291,277
	Male	201,444	232,173	236,571	579,395	642,194
	Female	191,620	220,634	225,780	581,385	649,083
Liver & Intrahepatic Bile Duct	Both Sexes	38,940	44,690	44,772	54,464	61,346
	Male	28,968	32,749	32,797	39,263	43,716
	Female	9,972	11,941	11,975	15,201	17,630
Pancreas	Both Sexes	36,831	44,775	44,811	49,363	58,920
	Male	18,821	22,954	22,966	24,251	29,201
	Female	18,010	21,821	21,845	25,112	29,719
Larynx	Both Sexes	32,033	37,848	38,327	87,910	98,553
	Male	25,889	30,586	30,982	70,533	78,905
	Female	6,144	7,262	7,345	17,377	19,648
Lung & Bronchus	Both Sexes	235,891	305,893	316,680	409,799	509,857
	Male	107,952	142,292	146,705	182,649	228,690
	Female	127,939	163,601	169,975	227,150	281,167
Melanoma of the Skin	Both Sexes	293,419	335,454	352,673	1,001,852	1,085,564
	Male	158,125	185,809	196,879	498,832	548,924
	Female	135,294	149,645	155,794	503,020	536,640
Breast	Female	888,374	963,711	1,026,553	3,011,973	3,194,990
Cervix	Female	39,026	41,272	41,346	216,287	222,528
Corpus & Uterus, NOS	Female	190,409	213,555	213,718	615,772	673,630
Ovary ^f	Female	61,283	70,222	70,275	181,920	204,129

^a U.S. 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER 9 registries and 1/1/2013 U.S. population estimates based on the average of 2012 and 2013 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 38 years (1975-2012)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2008-2012)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2008; Melanoma in 2009.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 38-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2013.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 38-year limited duration prevalence. The 2008 breast cancer is counted for the breast 5-year and 38-year limited duration prevalence.

In method (e) the 2008 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2009 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.22 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2013^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			38-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 38 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 38 Years ^d
Prostate	Male	996,735	1,077,771	1,077,866	2,849,303	3,033,987
Testis	Male	42,726	43,748	44,378	226,015	229,281
Urinary Bladder	Both Sexes	203,937	256,726	262,276	578,563	677,871
	Male	154,968	196,098	200,600	432,356	507,228
	Female	48,969	60,628	61,676	146,207	170,643
Kidney & Renal Pelvis	Both Sexes	158,086	192,740	195,379	384,082	448,864
	Male	97,484	120,269	122,119	228,920	270,059
	Female	60,602	72,471	73,260	155,162	178,805
Brain & Nervous System	Both Sexes	46,359	49,525	49,948	140,209	144,923
	Male	24,907	26,640	26,879	74,171	76,649
	Female	21,452	22,885	23,069	66,038	68,274
Thyroid	Both Sexes	194,792	218,107	218,918	600,285	645,059
	Male	43,408	51,452	51,619	130,022	143,922
	Female	151,384	166,655	167,299	470,263	501,137
Hodgkin Lymphoma	Both Sexes	37,358	39,844	39,912	181,370	186,607
	Male	20,235	21,627	21,671	94,047	96,687
	Female	17,123	18,217	18,241	87,323	89,920
Non-Hodgkin Lymphoma	Both Sexes	208,024	245,167	249,216	561,810	630,027
	Male	112,213	133,122	135,245	296,343	333,061
	Female	95,811	112,045	113,971	265,467	296,966
Myeloma	Both Sexes	60,408	71,647	71,915	95,457	110,345
	Male	32,121	39,215	39,380	51,385	60,395
	Female	28,287	32,432	32,535	44,072	49,950
Leukemia	Both Sexes	124,326	145,980	146,454	328,477	363,794
	Male	72,087	85,110	85,378	186,605	207,382
	Female	52,239	60,870	61,076	141,872	156,412
Acute Lymphocytic Leukemia	Both Sexes	17,063	17,597	17,597	74,508	75,300
	Male	9,316	9,590	9,590	40,643	41,001
	Female	7,747	8,007	8,007	33,865	34,299
Childhood (Ages 0-19)	Both Sexes	66,771	66,880	67,473	337,686	338,228
	Male	34,885	34,966	35,300	173,483	173,747
	Female	31,886	31,914	32,173	164,203	164,481
Kaposi Sarcoma	Both Sexes	7,288	7,954	7,954	26,999	28,478
	Male	6,806	7,404	7,404	25,587	26,891
	Female	482	550	550	1,412	1,587
Mesothelioma	Both Sexes	3,073	4,014	4,014	4,738	5,803
	Male	2,172	2,842	2,842	2,854	3,587
	Female	901	1,172	1,172	1,884	2,216

^a U.S. 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER 9 registries and 1/1/2013 U.S. population estimates based on the average of 2012 and 2013 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 38 years (1975-2012)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2008-2012)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2008; Melanoma in 2009.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 38-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2013.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 38-year limited duration prevalence. The 2008 breast cancer is counted for the breast 5-year and 38-year limited duration prevalence.

In method (e) the 2008 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2009 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.23
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2013^a
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	6,630,144	18,977	42,515	89,810	160,506	352,035	920,363	1,777,405	3,268,534
Females	7,510,110	17,057	36,959	90,895	235,457	635,354	1,378,596	1,900,156	3,215,637
Oral Cavity & Pharynx									
Males	200,280	28	471	1,653	3,431	13,626	48,036	65,705	67,330
Females	100,402	96	546	1,517	3,868	8,513	19,303	25,928	40,633
Esophagus									
Males	28,878	0	0	6	138	1,080	4,812	10,234	12,607
Females	7,979	0	0	22	34	189	1,353	2,058	4,324
Stomach									
Males	45,442	0	40	177	555	2,588	7,433	12,737	21,912
Females	34,401	0	27	231	757	2,445	4,965	7,644	18,332
Colon & Rectum									
Males	585,136	11	94	1,316	6,064	26,227	85,943	144,658	320,823
Females	592,420	0	230	1,444	6,369	23,982	73,478	117,870	369,046
Liver & Intrahep									
Males	39,334	612	484	604	641	1,590	11,144	15,911	8,350
Females	15,620	413	570	434	455	1,044	3,383	4,681	4,640
Pancreas									
Males	24,363	34	23	153	365	1,584	5,088	7,791	9,324
Females	25,257	0	12	288	536	1,593	4,671	7,156	11,001
Larynx									
Males	71,488	0	0	89	292	1,713	10,143	21,196	38,055
Females	17,593	0	0	28	144	847	3,543	5,051	7,979
Lung & Bronchus									
Males	186,030	34	75	517	1,120	4,955	23,975	55,413	99,941
Females	229,677	34	104	399	1,489	6,572	31,088	61,774	128,218
Melanoma of the Skin									
Males	509,094	56	696	4,938	17,619	45,039	99,914	144,398	196,432
Females	525,366	113	834	10,310	34,836	72,511	121,614	127,402	157,747

^a U.S. 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2013 U.S. population estimates based on the average of 2012 and 2013 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 38 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.23 - continued
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2013^a
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	15,781	0	0	11	115	703	1,911	4,527	8,514
Females	3,053,450	11	47	2,984	36,611	211,630	567,039	845,870	1,389,258
Cervix									
Females	248,920	0	68	1,821	14,820	40,574	59,368	60,139	72,130
Corpus & Uterus, NOS									
Females	635,437	11	23	629	6,040	25,247	93,125	182,278	328,082
Ovary ^d									
Females	195,767	105	1,012	3,796	6,939	18,071	41,987	52,895	70,961
Prostate									
Males	2,850,139	34	46	104	343	18,486	237,236	815,954	1,777,936
Urinary Bladder									
Males	438,068	68	105	551	2,315	9,819	42,325	105,894	276,992
Females	149,358	68	34	241	968	3,908	13,820	31,806	98,514
Kidney & Renal Pelvis									
Males	234,706	1,375	2,285	2,963	5,082	19,921	46,181	68,291	88,610
Females	159,630	1,455	2,581	3,065	5,082	12,617	28,144	40,702	65,983
Hodgkin Lymphoma									
Males	100,096	203	2,405	9,526	16,482	23,489	23,526	16,032	8,431
Females	93,449	34	2,104	9,344	16,640	22,518	21,509	13,067	8,232
Non-Hodgkin Lymphoma									
Males	300,417	927	3,738	8,182	14,080	29,312	57,496	77,491	109,191
Females	269,119	452	1,681	4,846	9,401	21,417	43,880	66,307	121,135
Myeloma									
Males	51,465	0	6	110	539	3,457	9,101	16,940	21,313
Females	44,223	0	0	45	377	2,237	7,664	12,935	20,965
Leukemia									
Males	189,019	6,519	13,341	13,964	12,067	15,409	26,626	39,493	61,600
Females	144,956	6,039	10,458	12,073	11,027	11,191	17,766	26,051	50,352
Acute Lymphocytic Leuk									
Males	42,395	5,394	11,202	10,799	6,965	4,601	1,951	925	559
Females	35,460	5,139	8,796	8,782	6,216	3,365	1,545	1,069	549

^a U.S. 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2013 U.S. population estimates based on the average of 2012 and 2013 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 38 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.